HFpEF Gene Therapy Signal Is Real But Evidence Tier Cannot Carry Approval Weight

Medera's SRD-002 Shows Durable Cardiac Improvement in HFpEF Trial

Medera Inc. announced 12-month data from its MUSIC-HFpEF Phase 1/2a clinical trial were presented as a Late-Breaking Clinical Trial at the European Society of Cardiology (ESC) Congress 2026. The trial evaluated SRD-002, an AAV1/SERCA2a gene therapy, in 10 adults with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF). Results showed durable improvement in cardiac filling pressures, with 80% of patients achieving normalization and an approximate 30% reduction in mean peak exercise pulmonary capillary wedge pressure. Supporting data indicated significant improvements in symptoms (83% of NYHA class III patients improved to class II) and quality of life (+17.8 KCCQ score). SRD-002 maintained a favorable safety profile with no serious adverse events.

• The MUSIC-HFpEF trial demonstrated significant and durable improvements in cardiac filling pressures, with 80% (8/10) of patients achieving normalization at 12 months. Mean peak exercise pulmonary capillary wedge pressure (PCWP) was reduced by approximately 30%, representing one of the largest sustained reductions reported in an interventional HFpEF trial to date, showing a dose-response and continued improvement from 6 to 12 months.
• Beyond hemodynamic improvements, SRD-002 treatment led to clinically meaningful benefits in patient symptoms and quality of life. 83% (5/6) of patients with baseline New York Heart Association (NYHA) class III symptoms improved to class II, and the mean Kansas City Cardiomyopathy Questionnaire (KCCQ) score improved by +17.8 points, indicating enhanced functional capacity.
• SRD-002 maintained a favorable safety profile across all 10 treated patients, with no treatment-related serious adverse events, dose-limiting toxicities, or Grade 3 or higher liver enzyme elevations. The intracoronary delivery method achieved targeted myocardial delivery with approximately 100- to 300-fold lower vector exposure compared to systemic intravenous AAV approaches, without requiring routine immunosuppression.
• These positive 12-month Phase 1/2a results support the advancement of SRD-002 into a randomized Phase 2b trial. Medera believes these findings underscore SRD-002's potential as a one-time, disease-modifying therapy for HFpEF, addressing a significant unmet need in cardiovascular medicine.

SRD-002 Shows Durable Efficacy and Favorable Safety in HFpEF

Recent clinical evidence has expanded the therapeutic landscape for heart failure with preserved ejection fraction (HFpEF), with several trials evaluating pharmacologic interventions across glycemic, neurohormonal, and incretin-based pathways. The studies below highlight key findings on efficacy and safety across distinct drug classes.

• DELIVER trial — Dapagliflozin (SGLT-2 inhibitor): DELIVER demonstrated that dapagliflozin reduces the combined risk of cardiovascular (CV) death or heart failure hospitalization (HHF) in patients with HFmrEF and HFpEF when added to a standard HF regimen, with the benefit primarily driven by reduction in HHF. A prognostic model derived from DELIVER data — incorporating 11 variables including NT-proBNP level, HF hospitalization within the past 6 months, creatinine level, diabetes, and treatment with a sodium-glucose cotransporter 2 inhibitor — showed good discrimination (C statistic at 1 year, 0.73; 95% CI, 0.71–0.75), outperforming the MAGGIC risk score (C statistic at 1 year, 0.60; 95% CI, 0.58–0.63; delta C statistic, 0.13; 95% CI, 0.10–0.15; P < .001) and NT-proBNP level alone.

• EMPEROR-Preserved trial — Empagliflozin (SGLT-2 inhibitor): EMPEROR-Preserved demonstrated that empagliflozin reduces CV death and HHF in patients with HFmrEF and HFpEF, with or without diabetes, when added to a standard HF regimen. Benefits appeared greatest in patients with left ventricular ejection fraction 41% up to approximately 65%.

• BRIDGE-DS study — Fixed-drug combination of dapagliflozin/sitagliptin (FDC D/S): In 168 T2DM patients with HF, FDC D/S produced significant (P < 0.0001) reductions in HbA1c, fasting plasma glucose, postprandial plasma glucose, NT-proBNP, systolic blood pressure, and diastolic blood pressure after 3 months, alongside significant (P < 0.0001) increases in ejection fraction and estimated glomerular filtration rate (eGFR). Common adverse events included urinary tract infections (29.8%), dehydration (17.9%), hypoglycemia (14.9%), and genital mycotic infection (6.6%).

• GLP-1RA meta-analysis (systematic review and meta-analysis) — Glucagon-like peptide-1 receptor agonists: Across six randomized controlled trials and four observational studies totaling 108,634 patients, GLP-1RA therapy reduced hospitalization due to heart failure by 37% (HR 0.63; 95% CI: 0.54–0.72) and favored reduction in MACE events (HR 0.73; 95% CI: 0.61–0.88; p=0.0008). Significant improvements were observed in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS; MD 8.55, 95% CI: 6.78–10.29; p<0.00001) and 6-minute walk distance (6MWD; MD 15.90, 95% CI: 15.35–16.46; p<0.00001). Safety signals included a significant increase in gastrointestinal effects (RR 1.56; 95% CI: 1.39–1.75; p<0.00001) and a lower risk of arrhythmias (RR 0.84; 95% CI: 0.79–0.90; p<0.0001).

Unpacking MUSIC-HFpEF Trial Design and SERCA2a Gene Therapy

Four major randomized clinical trials — I-PRESERVE, TOPCAT-Americas, PARAGON-HF, and DELIVER — have collectively enrolled over 16,900 patients with HFmrEF or HFpEF, generating a robust pooled dataset that has informed understanding of cardiovascular risk, treatment eligibility, and outcomes in this population. Each trial tested a distinct pharmacological agent against placebo or an active comparator, with varying ejection fraction thresholds and primary endpoint definitions.

The knowledge base does not have sufficient information on this aspect. regarding MUSIC-HFpEF trial design and SERCA2a gene therapy specifically, as no data on those subjects appear in the retrieved literature above.

Addressing HFpEF's Unmet Need with SRD-002's Potential

HFpEF constitutes up to 50% of all heart failure cases and has been recognized as the greatest single unmet need in cardiovascular medicine, yet its pathophysiology remains poorly understood and therapeutic targets are missing. The condition's highly heterogeneous nature — encompassing a wide range of phenotypic variations, comorbidities, and overlapping biological mechanisms including myocardial stiffness, coronary microvascular dysfunction, skeletal muscle mitochondrial impairment, and endothelial dysfunction — has made it exceptionally difficult to develop broadly effective therapies. Unlike heart failure with reduced ejection fraction, HFpEF is unified only by a preserved left ventricular ejection fraction ≥ 50%, a broad definition that overlooks important biological and clinical differences and has led to inconclusive results in large-scale therapeutic trials and suboptimal patient outcomes.

The diagnostic complexity of HFpEF further compounds therapeutic challenges. Traditional diagnostic methods frequently yield inconclusive results, necessitating invasive haemodynamic assessments as the gold standard for enhancing diagnostic accuracy. Phenotypic heterogeneity has driven interest in data-driven methodologies — including unsupervised machine learning, cluster analysis, and latent class modeling — to identify distinct phenotypes such as metabolic-obese, frail-elderly, atrial-fibrillation-dominant, cardiorenal, and pulmonary hypertension/right-heart phenotypes. However, methodological challenges including inconsistent input variables, lack of external validation, and limited integration with real-world data hinder translation of these phenotyping strategies into clinical practice.

On the pharmacological front, the evidence base remains fragmented. Mineralocorticoid receptor antagonists in HFpEF/HFmrEF patients showed only a 17% reduction in composite cardiovascular events and an 8% reduction in all-cause mortality, with cardiovascular mortality not significantly reduced (HR: 0.92, 95% CI: 0.82–1.02, P = 0.13), in contrast to the more substantial benefits observed in heart failure with reduced ejection fraction. Hyperkalemia risk is significantly higher with mineralocorticoid receptor antagonist use (RR: 2.19, 95% CI: 1.97–2.43, P < 0.00001), mandating close potassium monitoring. Challenges also persist in optimizing exercise prescriptions for phenotypically diverse HFpEF subpopulations, such as obese and elderly frail patients, and in validating long-term outcomes including mortality and hospitalization for non-pharmacological interventions.

SRD-002 Ignites Hope for HFpEF Gene Therapy

Heart failure with preserved ejection fraction (HFpEF) remains a formidable challenge in cardiology, affecting millions globally with a prognosis often as grim as its reduced ejection fraction counterpart. Characterized by exertional dyspnea and exercise intolerance, HFpEF is a complex syndrome with few targeted therapies, making any significant therapeutic advance highly anticipated. The recent 12-month data for Medera's SRD-002, an AAV1/SERCA2a gene therapy, presented at ESC Congress 2026, offers a compelling glimpse into a potential new era for HFpEF treatment.

The trial's findings are particularly noteworthy for demonstrating durable improvements in cardiac filling pressures, a critical physiological marker in HFpEF. With 80% of patients achieving normalization and a substantial reduction in mean peak exercise pulmonary capillary wedge pressure, SRD-002 appears to address a core pathophysiological mechanism. These objective measures are powerfully complemented by significant improvements in patient-reported outcomes, including NYHA functional class and quality of life scores, suggesting a meaningful impact on daily living. The favorable safety profile observed, with no serious adverse events, further bolsters confidence in this early-stage therapy.

However, the path forward for gene therapy in heart failure is not without its historical complexities. Previous attempts with AAV1/SERCA2a gene therapy in heart failure with reduced ejection fraction (HFrEF), notably the CUPID-2 trial, yielded disappointing results despite promising early data. This history underscores the inherent risks in translating early-phase success to larger, pivotal studies. The current data, while encouraging, stem from a very small cohort of just 10 patients. Expanding these findings to a broader, more diverse HFpEF population in larger, randomized trials will be crucial to confirm efficacy and safety. Furthermore, while AAV1 vectors generally exhibit good stability, the potential for immune responses, such as neutralizing antibodies, remains a consideration for long-term durability and potential re-dosing strategies.

Despite these considerations, the early signals from SRD-002 are strong enough to warrant significant attention. If these benefits are sustained and replicated in larger trials, SRD-002 could represent a transformative therapeutic option for HFpEF patients, potentially reshaping the treatment landscape and validating gene therapy as a viable approach for this challenging cardiovascular condition. The focus now shifts to the design and execution of subsequent clinical trials.